Also from this source

You just read:

PROCHIEVE 8% Vaginal Progesterone Gel Achieves Primary Endpoint in Phase III Study to Reduce Risk of Preterm Birth

News provided by

Watson Pharmaceuticals, Inc. , Columbia Laboratories, Inc.

Dec 06, 2010, 06:55 EST